Get started
Author

L. Uwer

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
2018 · Elisa Gobbini, Monia Ezzalfani, et al. · European Journal of Cancer · 276
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
2019 · Amélie Darlix, Guillaume Louvel, et al. · British Journal of Cancer · 228
PDF
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016
2020 · Elise Deluche, Alison Antoine, et al. · European Journal of Cancer · 186
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
2019 · Jean-Louis Pujol, Laurent Greillier, et al. · Journal of Thoracic Oncology · 179
PDF
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
2021 · T. Grinda, A. Antoine, et al. · ESMO Open · 142
PDF
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
2019 · Xavier Pivot, Gilles Romieu, et al. · The Lancet · 129
Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer
2011 · Lionel Uwer, Christine Rotonda, et al. · Health and Quality of Life Outcomes · 85
PDF
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
2016 · S. Delaloge, D. Pérol, et al. · Annals of Oncology · 71
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients
2018 · E. Jacquet, A. Lardy-Cléaud, et al. · European Journal of Cancer · 69
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
2024 · F. Poumeaud, M. Morisseau, et al. · British Journal of Cancer · 64
PDF
Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial
2010 · Etienne G.C. Brain, Cécile Mertens, et al. · Critical Reviews in Oncology/Hematology · 57
Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis
2018 · Elvire Pons-Tostivint, Youlia Kirova, et al. · Annals of Surgical Oncology · 55
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
2020 · Sophie Frank, Matthieu Carton, et al. · The Breast · 52
PDF
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort
2019 · David Pasquier, Amélie Darlix, et al. · European Journal of Cancer · 52
PDF
Impact of body mass index on overall survival in patients with metastatic breast cancer
2020 · Khalil Saleh, Matthieu Carton, et al. · The Breast · 50
PDF
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
2021 · M. Carausu, M. Carton, et al. · ESMO Open · 48
PDF
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
2020 · Guillaume Herbreteau, Alexandra Langlais, et al. · Journal of Clinical Medicine · 46
PDF
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
2017 · J. Gligorov, B. Ataseven, et al. · European Journal of Cancer · 46
Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program
2019 · William Jacot, Pierre‐Etienne Heudel, et al. · International Journal of Cancer · 37
Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis
2020 · Elvire Pons-Tostivint, Youlia Kirova, et al. · Radiotherapy and Oncology · 36
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort
2023 · Thomas Grinda, Alison Antoine, et al. · European Journal of Cancer · 35
Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
2022 · Ombline de Calbiac, Amélie Lusque, et al. · JAMA Network Open · 34
PDF
Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
2021 · Marion Bertho, Julien Fraisse, et al. · Therapeutic Advances in Medical Oncology · 32
Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial
2013 · C. Falandry, E. Brain, et al. · European Journal of Cancer · 30
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study
2022 · Florence Dalenc, Amélie Lusque, et al. · European Journal of Cancer · 29
Works count: 117
Citation count: 2,421
H-index: 26
I10-index: 36
Year
Topic
Type